It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Five years on from being the first person in the world to receive intravenous CRISPR treatment, Westmeath woman describes the clinical trial she participated in as ‘life-changing’ ...

Five years ago this month, in November 2020, medical history was made at Richmond Pharmacology when a patient received the ...

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery ...

Growing up in Tanzania, Prisca witnessed malaria as a daily reality with children missing school and families spending their limited savings on treatment. Witnessing how a preventable disease could ...

As reported in the Wall Street Journal, Armstrong has now officially entered the designer-baby business by funding heritable ...

From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized ...

The role of biomechanical cues in the progression of PM2.5-induced corneal disease was investigated, and PAI-2 was identified ...

This article examines some of the cell-based approaches that researchers are using to study acquired drug resistance and the ...

Cathie Wood, CEO of Ark Investment Management, typically focuses on small- and mid-cap technology stocks. But she occasionally ventures into megacap growth stocks. This strategy, which likely aims to ...

However, the causative organism was not identified until 1992 by molecular methods and was initially named Tropheryma ...